CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug ...

Childhood leukemia symptoms can be subtle. Learn how to recognize early warning signs and when to seek medical advice.

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

“Understanding how the repertoire of immune cells fits with the diverse landscape of brain cancer types can help us find new ...

B-cell lymphoma doesn’t always cause symptoms. If you have a slow-growing type, it might take months or years before symptoms start. As abnormal B cells multiply, they can cause areas that have ...